08Aug 2018


  • Cardiology, Mayo Clinic, Rochester, USA, 802 1st ST SW, Rochester, MN, USA.
  • Observer In Internal Medicine, Baylor Saint Luke\'s Medical Center, Houston, USA.
  • Internal Medicine, Jinnah Sindh Medical University, Karachi, PAK.
  • Internal Medicine, Harvard Medical College/Beth Israel Deaconess Medical Center, Boston, USA.
  • Internal Medicine, Fatima Jinnah Medical University, High Point, USA.
  • Oncology, Mayo Clinic, Rochester, MN, USA.
  • Internal Medicine, Liaquat University of Medical and Health Sciences Hospital Jamshoro Sindh Pakistan., Jamshoro, PAK.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Focal segmental glomerulosclerosis (FSGS) is one of the most important causes of end-stage renal disease in the United States. FSGS is more prevalent in young African American patients. It is commonly associated with various conditions such as genetic abnormalities, metabolic disorders, infections, and drug abuse. FSGS is a rare disease, and its association with hematological disorders is uncommon. In this study, we are documenting a case of the FSGS due to underlying multiple myeloma. The objective of this study is to emphasize the importance of excluding hematologic disorders in the older patients before diagnosing them with idiopathic FSGS. Early diagnosis and treatment of the underlying condition responsible for the FSGS can lead to complete remission of the FSGS, thus preventing complications such as renal failure.

  1. Collins AJ, Foley RN, Herzog C et al.: US Renal Data System 2012 annual data report. American Journal of Kidney Diseases. Am J Kidney Dis. 2012, 61:1-459. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21184928 DOI: 1053/j.ajkd.2011.11.015
  2. Kitiyakara C, Kopp JB, Eggers P: Trends in the epidemiology of focal segmental glomerulosclerosis. SeminNephrol. 2003, 23:172-82 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12704577 DOI:.1053/snep.2003.50025
  3. Dingli D, Larson DR, Plevak MF, Grande JP, Kyle RA: Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. Am J Kidney Dis. 2005, 46:278-282. PMID:https://www.ncbi.nlm.nih.gov/pubmed/16112046 DOI: 1053/j.ajkd.2005.05.004
  4. D?Agati VD: The spectrum of focal segmental glomerulosclerosis: new insights. CurrOpinNephrolHypertens. 2008, 17:271-281. PMID:https://www.ncbi.nlm.nih.gov/pubmed/18408478 DOI: 1097/MNH.0b013e3282f94a96
  5. D?Agati VD, Fogo AB, Bruijn JA, Jennette JC: Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004, 43:368. PMID:https://www.ncbi.nlm.nih.gov/pubmed/14750104 DOI: 1053/j.ajkd.2003.10.024
  6. D\'Agati VD, Kaskel FJ, Falk RJ: Focal segmental glomerulosclerosis. N Engl J Med. 2011 , 365:2398-2411. PMID:https://www.ncbi.nlm.nih.gov/pubmed/22187987 DOI: 1056/NEJMra1106556
  7. Deegens JK, Steenbergen EJ, Borm GF, Wetzels JF: Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population-epidemiology and outcome. Nephrol Dial Transplant. 2008, 23:186-192. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17704112 DOI: 1093/ndt/gfm523
  8. Shah S, Cavenagh J, Sheaf M, Thuraisingham RC: Remission of collapsing focal segmental glomerulosclerosis following chemotherapy for myeloma. Am J Kidney Dis. 2004, 43:10-12. PMID:https://www.ncbi.nlm.nih.gov/pubmed/14750118 DOI: 1053/j.ajkd.2003.10.036
  9. Calvo JV, Morales AU, Ramirez MS, Cuesta JT. :Focal and segmental glomerulosclerosis and non-Hodgkin\'s lymphoma. ClinNephrol. 2002 , 57:173-174. PMID/URL: https://www.ncbi.nlm.nih.gov/pubmed/11865822 DOI: NOT AVAILABLE
  10. Ashrafi F, Mortazavi M, Manouchehri N, Moghaddam NA, Nasri H, Sarrami AH: Focal segmental glomerulosclerosis, secondary amyloidosis and multiple myeloma. Pak J Med Sci. 2012, 28:345-347. URL: http://pjms.com.pk/index.php/pjms/article/view/2225.

[Wajih Ullah M, Rehman A, Ashraf F, Siddiq W, Latif Wa, Prasai K and Bai Joti. (2018); FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND MULTIPLE MYELOMA. Int. J. of Adv. Res. 6 (8). 181-185] (ISSN 2320-5407). www.journalijar.com

Muhammad Wajih Ullah
Mayo Clinic, Rochester, MN


Article DOI: 10.21474/IJAR01/7508       DOI URL: http://dx.doi.org/10.21474/IJAR01/7508

Share this article